Novartis C.E.O. Defends Company’s Decision to Withhold False Data From the F.D.A.. Novartis AG, Narasimhan, Vasant, Food and Drug Administration, Falsification of Data, Drugs (Pharmaceuticals), Genetic Engineering, Spinal Muscular Atrophy